712 North Inc. is a California-based pharmaceutical company spearheading personalized mitochondrial medicines for patients with Alzheimer’s dementia, heart failure and cancer. Our approach merges mitochondria biology with pharmaceutical drug development by targeting the proteases of the mitochondrial inner membrane. Positioned as pathway-company rather than focusing on a certain disease, we are poised to be first-in-class.